Predicting food allergy: The value of patient history reinforced.


Journal

Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028

Informations de publication

Date de publication:
05 2021
Historique:
revised: 10 08 2020
received: 24 06 2020
accepted: 13 08 2020
pubmed: 8 9 2020
medline: 22 5 2021
entrez: 7 9 2020
Statut: ppublish

Résumé

EAACI guidelines emphasize the importance of patient history in diagnosing food allergy (FA) and the need for studies investigating its value using standardized allergy-focused questionnaires. To determine the contribution of reaction characteristics, allergic comorbidities and demographics to prediction of FA in individuals experiencing food-related adverse reactions. Adult and school-age participants in the standardized EuroPrevall population surveys, with self-reported FA, were included. Penalized multivariable regression was used to assess the association of patient history determinants with "probable" FA, defined as a food-specific case history supported by relevant IgE sensitization. In adults (N = 844), reproducibility of reaction (OR 1.35 [95% CI 1.29-1.41]), oral allergy symptoms (OAS) (4.46 [4.19-4.75]), allergic rhinitis (AR) comorbidity (2.82 [2.68-2.95]), asthma comorbidity (1.38 [1.30-1.46]) and male sex (1.50 [1.41-1.59]) were positively associated with probable FA. Gastrointestinal symptoms (0.88 [0.85-0.91]) made probable FA less likely. The AUC of a model combining all selected predictors was 0.85 after cross-validation. In children (N = 670), OAS (2.26 [2.09-2.44]) and AR comorbidity (1.47 [CI 1.39-1.55]) contributed most to prediction of probable FA, with a combined cross-validation-based AUC of 0.73. When focusing on plant foods, the dominant source of FA in adults, the pediatric model also included gastrointestinal symptoms (inverse association), and the AUC increased to 0.81. In both adults and school-age children from the general population, reporting of OAS and of AR comorbidity appear to be the strongest predictors of probable FA. Patient history particularly allows for good discrimination between presence and absence of probable plant FA.

Sections du résumé

BACKGROUND
EAACI guidelines emphasize the importance of patient history in diagnosing food allergy (FA) and the need for studies investigating its value using standardized allergy-focused questionnaires.
OBJECTIVE
To determine the contribution of reaction characteristics, allergic comorbidities and demographics to prediction of FA in individuals experiencing food-related adverse reactions.
METHODS
Adult and school-age participants in the standardized EuroPrevall population surveys, with self-reported FA, were included. Penalized multivariable regression was used to assess the association of patient history determinants with "probable" FA, defined as a food-specific case history supported by relevant IgE sensitization.
RESULTS
In adults (N = 844), reproducibility of reaction (OR 1.35 [95% CI 1.29-1.41]), oral allergy symptoms (OAS) (4.46 [4.19-4.75]), allergic rhinitis (AR) comorbidity (2.82 [2.68-2.95]), asthma comorbidity (1.38 [1.30-1.46]) and male sex (1.50 [1.41-1.59]) were positively associated with probable FA. Gastrointestinal symptoms (0.88 [0.85-0.91]) made probable FA less likely. The AUC of a model combining all selected predictors was 0.85 after cross-validation. In children (N = 670), OAS (2.26 [2.09-2.44]) and AR comorbidity (1.47 [CI 1.39-1.55]) contributed most to prediction of probable FA, with a combined cross-validation-based AUC of 0.73. When focusing on plant foods, the dominant source of FA in adults, the pediatric model also included gastrointestinal symptoms (inverse association), and the AUC increased to 0.81.
CONCLUSIONS
In both adults and school-age children from the general population, reporting of OAS and of AR comorbidity appear to be the strongest predictors of probable FA. Patient history particularly allows for good discrimination between presence and absence of probable plant FA.

Identifiants

pubmed: 32894581
doi: 10.1111/all.14583
pmc: PMC8246712
doi:

Substances chimiques

Allergens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1454-1462

Subventions

Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/F/00041800
Pays : United Kingdom

Informations de copyright

© 2020 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Références

J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1920-1928.e11
pubmed: 30898689
Clin Allergy. 1987 Jan;17(1):33-42
pubmed: 3829369
Allergy. 2005;60 Suppl 79:19-24
pubmed: 15842229
Allergy. 2009 Oct;64(10):1493-7
pubmed: 19385958
Allergy. 2015 Sep;70(9):1079-90
pubmed: 26095197
Allergy. 2014 Mar;69(3):365-71
pubmed: 24372074
Allergy. 2016 Sep;71(9):1241-55
pubmed: 27138061
Nutrients. 2018 Oct 16;10(10):
pubmed: 30332840
J Allergy Clin Immunol. 2018 Jan;141(1):41-58
pubmed: 29157945
Clin Transl Allergy. 2015 Feb 19;5:7
pubmed: 25741437
Allergy. 2021 May;76(5):1454-1462
pubmed: 32894581
J Allergy Clin Immunol. 2011 Mar;127(3):633-9.e1-3
pubmed: 21377032
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2736-2746.e9
pubmed: 32330668
Eur Respir J. 1994 May;7(5):954-60
pubmed: 8050554
J Allergy Clin Immunol Pract. 2013 Nov-Dec;1(6):632-8.e1
pubmed: 24565711
Allergy. 2014 Aug;69(8):1008-25
pubmed: 24909706

Auteurs

Sarah A Lyons (SA)

Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.

André C Knulst (AC)

Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.

Peter G J Burney (PGJ)

National Heart and Lung Institute, Imperial College London, London, UK.

Montserrat Fernandez-Rivas (M)

Allergy Department, Hospital Clinico San Carlos, IdISSC, ARADyAL, RD16/0006/0009, Madrid, Spain.

Barbara K Ballmer-Weber (BK)

Allergy Unit, Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.
Faculty of Medicine, University of Zürich, Zürich, Switzerland.
Clinic for Dermatology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland.

Laura Barreales (L)

Clinical Epidemiology Unit, Preventive Medicine Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.

Christian Bieli (C)

Department of Paediatric Pulmonology, University Children's Hospital, Zürich, Switzerland.

Michael Clausen (M)

Children's Hospital, Landspitali University Hospital, Reykjavik, Iceland.

Ruta Dubakiene (R)

Medical Faculty, Vilnius University, Vilnius, Lithuania.

Cristina Fernandez-Perez (C)

Clinical Epidemiology Unit, Preventive Medicine Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.

Monika Jedrzejczak-Czechowicz (M)

Department of Immunology, Rheumatology and Allergy, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.

Marek L Kowalski (ML)

Department of Immunology, Rheumatology and Allergy, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.

Ischa Kummeling (I)

National Heart and Lung Institute, Imperial College London, London, UK.

Tanya Kralimarkova (T)

Clinical Centre of Allergology of the Alexandrovska Hospital, Medical University of Sofia, Sofia, Bulgaria.

Tihomir B Mustakov (TB)

Clinical Centre of Allergology of the Alexandrovska Hospital, Medical University of Sofia, Sofia, Bulgaria.

Harmieke van Os-Medendorp (H)

Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.
Saxion University of Applied Sciences, Deventer, The Netherlands.

Nikolaos G Papadopoulos (NG)

Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.
Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.

Todor A Popov (TA)

University Hospital Sv. Ivan Rilski, Sofia, Bulgaria.

James Potts (J)

National Heart and Lung Institute, Imperial College London, London, UK.

Serge A Versteeg (SA)

Department of Experimental Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Paraskevi Xepapadaki (P)

Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.

Paco M J Welsing (PMJ)

Division of Internal Medicine and Dermatology, University Medical Center Utrecht, Utrecht University, The Netherlands.

Clare Mills (C)

Division of Infection, Immunity and Respiratory Medicine, Manchester Institute of Biotechnology & Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.

Ronald van Ree (R)

Department of Experimental Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Department of Otorhinolaryngology, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Thuy-My Le (TM)

Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH